Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells.
Hypoxia is a major pathophysiological condition for the induction of angiogenesis, which is a crucial aspect of growth in solid tumors. In mammalian cells, the transcriptional response to oxygen deprivation is largely mediated by hypoxia-inducible factor 1 (HIF-1), a heterodimer composed of HIF-1alpha and HIF-1beta subunits. However, the response of endothelial cells to hypoxia and the specific involvement of HIF-alpha subunits in this process are still poorly understood. We show that human umbilical vein endothelial cells (HUVECs) cultured in the absence of growth factors survive and form tubelike structures when cultured under hypoxic, but not normoxic, conditions. HUVECs expressed both HIF-1alpha and HIF-2alpha when cultured under hypoxic conditions. Transfection of HIF-1alpha, but not HIF-2alpha, siRNA to HUVECs completely abrogated hypoxic induction of cords. Neutralizing antibodies to bFGF, but not IGF-1, VEGF, or PDGF-BB, blocked survival and sprouting of HUVECs under hypoxic conditions, suggesting the existence of an autocrine loop induced by low oxygen levels. Notably, bFGF-dependent induction of cord formation under normoxic conditions required HIF-1alpha activity, which was also essential for hypoxic induction of bFGF mRNA and protein expression. These results uncover the existence of an HIF-1alpha-bFGF amplification pathway that mediates survival and sprouting of endothelial cells under hypoxic conditions.
Calvani
Maura
M
DTP-Tumor Hypoxia Laboratory, Bldg 432, Rm 218, National Cancer Institute at Frederick, MD 21702, USA.
Rapisarda
Annamaria
A
Uranchimeg
Badarch
B
Shoemaker
Robert H
RH
Melillo
Giovanni
G
D051784:Aryl Hydrocarbon Receptor Nuclear Translocator / Q000494:pharmacology; D015687:Cell Hypoxia / Q000502:physiology*; D002460:Cell Line; D004730:Endothelium, Vascular / Q000502:physiology*; D005312:Fetal Blood / Q000166:cytology / Q000502:physiology; D016222:Fibroblast Growth Factor 2 / Q000502:physiology*; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000494:pharmacology*; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology*; D034741:RNA, Small Interfering / Q000235:genetics; D019772:Topotecan / Q000494:pharmacology; D014162:Transfection; D014471:Umbilical Veins
C497396:ARNT protein, human; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D034741:RNA, Small Interfering; D016222:Fibroblast Growth Factor 2; D051784:Aryl Hydrocarbon Receptor Nuclear Translocator; D019772:Topotecan